SCHEMBL4979050

SCHEMBL4979050

Cc1ccc(C(C)N2CCc3c(ncnc3N3CCN(C4CCC4)CC3)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 7/20 0.45
CHRM1 P11229 7/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HRH1 P35367 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
HIF1A Q16665 1/20 0.37
TSHR P16473 1/20 0.36
KDM2B Q8NHM5 3/20 0.35
CHRM4 P08173 1/20 0.35
CHRM3 P20309 1/20 0.35
TLR7 Q9NYK1 2/20 0.35
P2RX3 P56373 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4978660 0.93 HRH1 (0.42) CHRM2CHRM1MEN1KMT2AHRH1
SCHEMBL4980602 0.91 ALDH1A1 (0.42) CHRM2CHRM1MEN1KMT2AHRH1
SCHEMBL4976132 0.91 HRH3 (0.47) CHRM2CHRM1MEN1KMT2AHRH1
SCHEMBL4976871 0.90 HRH3 (0.40) CHRM2CHRM1MEN1KMT2AHRH1
SCHEMBL4978589 0.89 HRH1 (0.40) CHRM2CHRM1MEN1KMT2AHRH1
SCHEMBL4978021 0.89 HRH1 (0.41) CHRM2CHRM1MEN1KMT2AHRH1
SCHEMBL4978961 0.86 HRH3 (0.39) CHRM2CHRM1MEN1KMT2AHRH1
SCHEMBL4978482 0.84 OGA (0.41)
SCHEMBL4978092 0.84 ALDH1A1 (0.42) MEN1KMT2AHRH1HRH3ALDH1A1
SCHEMBL4978253 0.83 HRH3 (0.44) MEN1KMT2AHRH1HRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION 2008-02-28 US disclosed
WO-2007146122-A2 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051387-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES HRH3, HRH4, HRH2 CHRM2 313/4885CHRM1 372/4885MEN1 4419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.